康艾注射液联合FOLFIRI方案治疗结直肠癌的Meta分析(1)
[摘要]目的 探討及系统性评价康艾注射联合FOLFIRI化疗方案治疗结直肠癌的临床效果及安全性。方法 计算机检索Pubmed，the Cochrane Library，SCI，CNKI，VIP，CBM，Wan Fang Database，检索时间截至2016年8月10日。收集康艾注射液联合FOLFIRI化疗方案应用于结直肠癌的临床随机对照研究，各研究间有效率、生存质量改善率、不良反应相关数据相加组合，对比、分析两药联合组与单用FOLFIRI方案组的疗效差异。由两名研究者分别按照纳入和排除标准独立搜索选择文献、提取资料，采用Revman 5.0软件进行Meta分析。结果 共纳入4项研究，涉及患者299名。Meta分析结果显示，康艾注射液联合FOLFIRI化疗方案(联合组)与单纯FOLFIRI化疗方案组治疗后的有效率差异有统计学意义(P<0.01；OR=1.82，95%CI=1.16～2.87)；联合组对结直肠癌的生活质量改善率，与单纯FOLFIRI方案比较，差异有统计学意义(P<0.01；OR=2.32，95%CI=1.33～4.07)；联合组患者白细胞减少发生率明显低于单纯FOLFIRI化疗方案组，差异有统计学意义(P<0.01；OR=51.46，95%CI=10.36～255.67)；联合组患者恶心呕吐发生率明显低于单纯FOLFIRI化疗方案组，差异有统计学意义(P<0.01；OR=0.33，95%CI=0.15～0.73)，而血小板降低、肝肾功能损害、腹泻方面两组差异均无统计学意义(P>0.05)。结论 在治疗中晚期结直肠癌效果及减少不良反应方面，康艾注射液联合FOLFIRI化疗方案优于单纯FOLFIRI化疗方案。
[关键词]康艾注射液；FOLFIRI；结直肠癌；Meta分析
[中图分类号] R735.3+4 [文献标识码] A [文章编号] 1674-4721(2017)05(a)-0004-06
[Abstract]Objective To discuss and systematically evaluate the clinical effect and safety of Kangai Injection combined with FOLFIRI for the treatment of colorectal cancer.Methods Pubmed，the Cochrane Library，SCI，CNKI，VIP，CBM，Wan Fang Database were searched using computer.August 10，2016 was search deadline. Clinical randomized controlled study of Kangai Injection combined with FOLFIRI chemotherapy plan applied in colorectal cancer was collected，and the effective rate，the improvement rate of quality of life and adverse reaction related data among the studies were added and combined.Differences of curative effect of two drug combination group and single FOLFIRI group were compared and analyzed.According to the inclusion and exclusion criteria，two researchers independently selected and searched the literature，extracted the data and Meta analysis was conducted using Revman 5.0 software.Results A total of 4 studies were included involving 299 patients.Meta analysis results showed that there was a statistical difference of the effective rate between the Kangai Injection combined with FOLFIRI chemotherapy plan (the combined group) and single FOLFIRI chemotherapy plan group after treatment (P<0.01；OR=1.82，95%CI=1.16-2.87).There was a statistical difference of the improvement rate of quality of life between the combined group and single FOLFIRI plan (P<0.01；OR=2.32，95%CI=1.33-4.07).The incidence rate of white blood cell reduction in the combination group was statistically significant lower than that of the single FOLFIRI chemotherapy plan group，and there was a statistical difference (P<0.01；OR=51.46，95%CI=10.36-255.67).The incidence rate of nausea and vomiting in the combination group was statistically significant lower than that of the FOLFIRI chemotherapy group and there was a statistical difference (P<0.01；OR=0.33，95%CI=0.15-0.73).There was no significant difference between the two groups in the aspects of platelet reduction，liver and renal function damage and diarrhea (P>0.05).Conclusion Kangai Injection combined with FOLFIRI chemotherapy plan is better than single FOLFIRI chemotherapy plan in the aspects of effect for treating advanced colorectal cancer and reducing the adverse reaction. (张丽娜 汪园园 邱超平)
[关键词]康艾注射液；FOLFIRI；结直肠癌；Meta分析
[中图分类号] R735.3+4 [文献标识码] A [文章编号] 1674-4721(2017)05(a)-0004-06
[Abstract]Objective To discuss and systematically evaluate the clinical effect and safety of Kangai Injection combined with FOLFIRI for the treatment of colorectal cancer.Methods Pubmed，the Cochrane Library，SCI，CNKI，VIP，CBM，Wan Fang Database were searched using computer.August 10，2016 was search deadline. Clinical randomized controlled study of Kangai Injection combined with FOLFIRI chemotherapy plan applied in colorectal cancer was collected，and the effective rate，the improvement rate of quality of life and adverse reaction related data among the studies were added and combined.Differences of curative effect of two drug combination group and single FOLFIRI group were compared and analyzed.According to the inclusion and exclusion criteria，two researchers independently selected and searched the literature，extracted the data and Meta analysis was conducted using Revman 5.0 software.Results A total of 4 studies were included involving 299 patients.Meta analysis results showed that there was a statistical difference of the effective rate between the Kangai Injection combined with FOLFIRI chemotherapy plan (the combined group) and single FOLFIRI chemotherapy plan group after treatment (P<0.01；OR=1.82，95%CI=1.16-2.87).There was a statistical difference of the improvement rate of quality of life between the combined group and single FOLFIRI plan (P<0.01；OR=2.32，95%CI=1.33-4.07).The incidence rate of white blood cell reduction in the combination group was statistically significant lower than that of the single FOLFIRI chemotherapy plan group，and there was a statistical difference (P<0.01；OR=51.46，95%CI=10.36-255.67).The incidence rate of nausea and vomiting in the combination group was statistically significant lower than that of the FOLFIRI chemotherapy group and there was a statistical difference (P<0.01；OR=0.33，95%CI=0.15-0.73).There was no significant difference between the two groups in the aspects of platelet reduction，liver and renal function damage and diarrhea (P>0.05).Conclusion Kangai Injection combined with FOLFIRI chemotherapy plan is better than single FOLFIRI chemotherapy plan in the aspects of effect for treating advanced colorectal cancer and reducing the adverse reaction. (张丽娜 汪园园 邱超平)